Synopsis
Synopsis
0
KDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Amide, Procaine
2. Apo-procainamide
3. Biocoryl
4. Hydrochloride, Procainamide
5. Novocainamide
6. Novocamid
7. Procainamide
8. Procaine Amide
9. Procamide
10. Procan
11. Procan Sr
12. Procanbid
13. Pronestyl
14. Rhythmin
1. 614-39-1
2. Procainamide Hcl
3. Pronestyl
4. Procanbid
5. Procapan
6. Procan
7. Procan Sr
8. 4-amino-n-[2-(diethylamino)ethyl]benzamide Hydrochloride
9. Procainamide (hydrochloride)
10. Pronestyl-sr
11. Amidoprocaine
12. Cardiorytmin
13. Benzamide, 4-amino-n-[2-(diethylamino)ethyl]-, Monohydrochloride
14. 4-amino-n-[2-(diethylamino)ethyl]benzamide;hydrochloride
15. Nsc-757279
16. Mls000069436
17. Chebi:8429
18. Si4064o0lx
19. Benzamide, 4-amino-n-(2-(diethylamino)ethyl)-, Monohydrochloride
20. Smr000059079
21. Procainhydrochlorid
22. Procainii Chloridum
23. Promide Hydrochloride
24. Procapan Hydrochloride
25. Novocamid Hydrochloride
26. Procamide Hydrochloride
27. Procardyl Hydrochloride
28. 4-amino-n-(2-(diethylamino)ethyl)benzamide Hydrochloride
29. Procan-sr Hydrochloride
30. Procaine Amide Hydrochloride
31. Supicane Amide Hydrochloride
32. Procainamidehydrochloride
33. Ccris 7143
34. 4-amino-n-(2-diethylaminoethyl)benzamide Hydrochloride
35. Sr-01000000022
36. Cas-614-39-1
37. Einecs 210-381-7
38. Mfcd00012998
39. 7699-39-0
40. Unii-si4064o0lx
41. Procanbid (tn)
42. Pronestyl (tn)
43. Procainamide Hydrochloride [usp:jan]
44. Procan Sr (tn)
45. 4-aminobenzoesaeure-2-diethylaminoethylester Hydrochlorid
46. P-amino-n-(2-(diethylamino)ethyl)benzamide Hydrochloride
47. Pronestyl Hydrochloride
48. 4-amino-n-(2-(diethylamino)ethyl)benzamide Monohydrochloride
49. P-amino-n-(2-(diethylamino)ethyl)benzamide Monohydrochloride
50. Opera_id_1543
51. Procainamidi Hydrochloridum
52. Chembl605
53. Epitope Id:140114
54. Dsstox_cid_29382
55. Dsstox_rid_83497
56. Dsstox_gsid_49422
57. Schembl40758
58. Mls001148635
59. Spectrum1500503
60. Dtxsid2049422
61. Benzamide, P-amino-n-(2-(diethylamino)ethyl)-, Hydrochloride
62. Hms1569c15
63. Hms1920l04
64. Pharmakon1600-01500503
65. Act08464
66. Amy22225
67. Bcp28404
68. Hy-a0084
69. Tox21_202855
70. Tox21_500995
71. Ccg-39233
72. Nsc757279
73. S4294
74. Akos008056264
75. Ac-7552
76. Ks-5258
77. Lp00995
78. Nc00535
79. Nsc 757279
80. Procainamide Hydrochloride (jp17/usp)
81. Procainamide Hydrochloride [mi]
82. Procainamide Hydrochloride [jan]
83. Ncgc00094291-01
84. Ncgc00094291-02
85. Ncgc00094291-03
86. Ncgc00094291-04
87. Ncgc00094291-05
88. Ncgc00260401-01
89. Ncgc00261680-01
90. Procainamide Hydrochloride [mart.]
91. Procainamide Hydrochloride [vandf]
92. Procainamide Hydrochloride [usp-rs]
93. Procainamide Hydrochloride [who-dd]
94. Procainamide Hydrochloride [who-ip]
95. Db-053889
96. Procainamide Hydrochloride, >=98% (hplc)
97. Eu-0100995
98. Ft-0603493
99. Sw196878-3
100. Vu0239777-5
101. A14240
102. Bim-0050968.0001
103. D00477
104. D97622
105. P 9391
106. Procainamide Hydrochloride [orange Book]
107. 4-amino-n-(2-diethylamino-ethyl)-benzamide Hcl
108. Procainamide Hydrochloride [ep Monograph]
109. Procainamide Hydrochloride [usp Monograph]
110. Procainamidi Hydrochloridum [who-ip Latin]
111. Procainamide Hydrochloride, Purum, >=98.0% (at)
112. Sr-01000000022-2
113. Sr-01000000022-6
114. W-105155
115. Procainamide Hydrochloride 100 Microg/ml In Methanol
116. Q27108080
117. F0850-6742
118. 4-amino-n-[2'-(diethylamino)ethyl]benzamide Hydrochloride
119. 4-amino-n-[2-(diethylamino)ethyl]-benzamide Hydrochloride
120. P-amino-n-(2-(diethylamino)ethy)benzamide Monohydrochloride
121. Benzamide, 4-amino-n-(2-(diethylamino)ethyl)-, Hydrochloride (1:1)
122. Procainamide Hydrochloride, European Pharmacopoeia (ep) Reference Standard
123. 4-amino-n-(2-(diethylamino)ethyl)benzamide Monohydrochloride [who-ip]
124. Procainamide Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
125. Procainamide Hydrochloride, United States Pharmacopeia (usp) Reference Standard
Molecular Weight | 271.78 g/mol |
---|---|
Molecular Formula | C13H22ClN3O |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 6 |
Exact Mass | 271.1451400 g/mol |
Monoisotopic Mass | 271.1451400 g/mol |
Topological Polar Surface Area | 58.4 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 221 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Procainamide hydrochloride |
Drug Label | Procainamide Hydrochloride Injection, USP is a sterile, nonpyrogenic solution of procainamide hydrochloride in water for injection. Each milliliter of the 2 mL vial contains procainamide hydrochloride 500 mg; methylparaben 1 mg and sodium metabisulfi... |
Active Ingredient | Procainamide hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/ml; 100mg/ml |
Market Status | Prescription |
Company | Hospira |
2 of 2 | |
---|---|
Drug Name | Procainamide hydrochloride |
Drug Label | Procainamide Hydrochloride Injection, USP is a sterile, nonpyrogenic solution of procainamide hydrochloride in water for injection. Each milliliter of the 2 mL vial contains procainamide hydrochloride 500 mg; methylparaben 1 mg and sodium metabisulfi... |
Active Ingredient | Procainamide hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | 500mg/ml; 100mg/ml |
Market Status | Prescription |
Company | Hospira |
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-03-28
Pay. Date : 2019-02-28
DMF Number : 33216
Submission : 2018-09-29
Status : Active
Type : II
Certificate Number : R0-CEP 2019-119 - Rev 01
Issue Date : 2023-05-15
Type : Chemical
Substance Number : 567
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-01-04
Pay. Date : 2021-10-27
DMF Number : 36402
Submission : 2021-10-30
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-06-24
Pay. Date : 2013-11-21
DMF Number : 25461
Submission : 2011-10-07
Status : Active
Type : II
NDC Package Code : 58747-7010
Start Marketing Date : 1986-02-12
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-19
Pay. Date : 2013-06-06
DMF Number : 4911
Submission : 1983-04-18
Status : Active
Type : II
NDC Package Code : 22568-1026
Start Marketing Date : 2021-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2020-08-17
Valid Till : 2023-06-22
Written Confirmation Number : WC-0404A2
Address of the Firm :
NDC Package Code : 69575-4028
Start Marketing Date : 2021-12-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (30kg/30kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2021-02-26
Valid Till : 2023-06-22
Written Confirmation Number : WC-0404A3
Address of the Firm :
NDC Package Code : 69575-4028
Start Marketing Date : 2021-12-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (30kg/30kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2020-08-17
Valid Till : 2023-06-22
Written Confirmation Number : WC-0404
Address of the Firm :
NDC Package Code : 69575-4028
Start Marketing Date : 2021-12-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (30kg/30kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2020-08-17
Valid Till : 2023-06-22
Written Confirmation Number : WC-0404A2
Address of the Firm :
NDC Package Code : 69575-4028
Start Marketing Date : 2021-12-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (30kg/30kg)
Marketing Category : BULK INGREDIENT
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2133
Submission : 1973-07-23
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2188
Submission : 1973-10-29
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Related Excipient Companies
Excipients by Applications
Global Sales Information
REF. STANDARDS & IMPURITIES
Procainamide Hydrochloride (200 mg)
CAS Number : 614-39-1
Quantity Per Vial :
Price ($) : 230
Catalog Number : 1563502
Current Lot : I1I286
Previous Lot : I0I286 (30-SEP-2017)
NDC Code :
ABOUT THIS PAGE
22
PharmaCompass offers a list of Procainamide Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Procainamide Hydrochloride manufacturer or Procainamide Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Procainamide Hydrochloride manufacturer or Procainamide Hydrochloride supplier.
PharmaCompass also assists you with knowing the Procainamide Hydrochloride API Price utilized in the formulation of products. Procainamide Hydrochloride API Price is not always fixed or binding as the Procainamide Hydrochloride Price is obtained through a variety of data sources. The Procainamide Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Procainamide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Procainamide, including repackagers and relabelers. The FDA regulates Procainamide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Procainamide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Procainamide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Procainamide supplier is an individual or a company that provides Procainamide active pharmaceutical ingredient (API) or Procainamide finished formulations upon request. The Procainamide suppliers may include Procainamide API manufacturers, exporters, distributors and traders.
click here to find a list of Procainamide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Procainamide DMF (Drug Master File) is a document detailing the whole manufacturing process of Procainamide active pharmaceutical ingredient (API) in detail. Different forms of Procainamide DMFs exist exist since differing nations have different regulations, such as Procainamide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Procainamide DMF submitted to regulatory agencies in the US is known as a USDMF. Procainamide USDMF includes data on Procainamide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Procainamide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Procainamide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Procainamide Drug Master File in Japan (Procainamide JDMF) empowers Procainamide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Procainamide JDMF during the approval evaluation for pharmaceutical products. At the time of Procainamide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Procainamide suppliers with JDMF on PharmaCompass.
A Procainamide CEP of the European Pharmacopoeia monograph is often referred to as a Procainamide Certificate of Suitability (COS). The purpose of a Procainamide CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Procainamide EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Procainamide to their clients by showing that a Procainamide CEP has been issued for it. The manufacturer submits a Procainamide CEP (COS) as part of the market authorization procedure, and it takes on the role of a Procainamide CEP holder for the record. Additionally, the data presented in the Procainamide CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Procainamide DMF.
A Procainamide CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Procainamide CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Procainamide suppliers with CEP (COS) on PharmaCompass.
A Procainamide written confirmation (Procainamide WC) is an official document issued by a regulatory agency to a Procainamide manufacturer, verifying that the manufacturing facility of a Procainamide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Procainamide APIs or Procainamide finished pharmaceutical products to another nation, regulatory agencies frequently require a Procainamide WC (written confirmation) as part of the regulatory process.
click here to find a list of Procainamide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Procainamide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Procainamide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Procainamide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Procainamide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Procainamide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Procainamide suppliers with NDC on PharmaCompass.
Procainamide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Procainamide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Procainamide GMP manufacturer or Procainamide GMP API supplier for your needs.
A Procainamide CoA (Certificate of Analysis) is a formal document that attests to Procainamide's compliance with Procainamide specifications and serves as a tool for batch-level quality control.
Procainamide CoA mostly includes findings from lab analyses of a specific batch. For each Procainamide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Procainamide may be tested according to a variety of international standards, such as European Pharmacopoeia (Procainamide EP), Procainamide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Procainamide USP).